Attitudes of Oncology Nurses Concerning Pharmacogenomics

Abstract

Therefore, future research on the assessment of attitudes of oncology nurses concerning pharmacogenomics should incorporate these themes.

Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review

“…A significant barrier to routine PGx implementation in oncology practice is the cost of testing, which was reported in eight studies 21,24,27,31,35,38–41 . Both oncology HCPs and patients voiced their concerns about the cost and lack of health insurance coverage for PGx tests that impede the utilization of PGx screening in routine clinical care, despite high willingness for PGx‐guided oncology treatment.…”

“…It is evident that PGx education is a key driver to promoting PGx integration in clinical oncology. [22][23][24][25][26]32,38 Across studies, most HCPs expressed a high desire for cancer PGx education as part of their continuing professional education. Notably, Dodson undertook a comparison of oncology nurses' knowledge score pre-and post-education intervention and demonstrated that continuing PGx education is effective in improving nurses' short-term knowledge of genomic and PGx information (Table 2).…”

“…Overall, both HCPs and consumers perceived PGx in oncology positively, in particular the potential of PGx in guiding cancer treatment to improve efficacy and minimize toxicity. [19][20][21][22][23][24][26][27][28][29][30]32,35,37,[39][40][41] It was found that there is a high level of acceptance of PGx testing (~90% across studies) and information among consumers, including those who had PGx testing and those who had not had PGx testing and were asked hypothetical questions about PGx, [19][20][21][27][28][29]32,40 and two studies reported that patients with cancer expressed high willingness to pay for PGx tests. 21,29 Two studies, Dodson and Przybylski et al, 23,38 assessed the prior PGx education HCPs had received and found that most had no formalized PGx education during their undergraduate training.…”

“…Oncology HCPs viewed consensus guidelines with evidence from randomized controlled trials and clear impact on patient outcomes as instrumental in promoting use of PGx testing in routine oncology practice. 22,24,32,37 Succinct and concise PGx-guided dosing guidelines embedded in electronic health records was also recommended by HCPs. 22 Streamlined and regulated PGx testing Streamlined PGx ordering systems and authority-regulated testing were found to be important to facilitate PGx integration into routine practice.…”

“…22 Streamlined and regulated PGx testing Streamlined PGx ordering systems and authority-regulated testing were found to be important to facilitate PGx integration into routine practice. 24,32,37,40 HCPs regarded consistency of PGx testing, test validity, usability, and integrated authorization procedures as enablers.…”